Most fly-in-fly-out (FIFO) and remote energy operations have invested significantly in oral fluid screening and breath alcohol testing at the point of site entry. Very few have extended their programs to include surface drug testing. That leaves a gap. Oral fluid and breath testing assess whether a person is fit for duty at the moment they are tested. Surface testing does something different. It detects drug residue on physical surfaces such as steering wheels, accommodation fixtures, desk surfaces, door handles and communal areas. It does not test a person. It tests an environment.
This distinction matters because it opens a new layer of risk management that operates alongside personal screening without the same privacy and consent considerations. For remote sites where workers live in shared accommodation, operate fleet vehicles and use communal facilities for weeks at a time, the environment itself can carry evidence of drug activity that personal testing alone will never detect.
Andatech has spent more than 20 years helping organisations across mining, energy and construction implement drug and alcohol testing programs. In recent years, a growing number of FIFO and remote site operators have added surface testing to their existing programs. This article explains how surface testing works, where it applies, how it fits within a layered testing approach and why the investment delivers measurable returns.
What Is Surface Drug Testing And How Does It Differ From Personal Screening?
Surface drug testing detects the presence of drug residue on physical objects and surfaces. A collection swab is used to gather a sample from the target area. That sample is then analysed using immunoassay technology to identify specific drug compounds. The process is rapid, non-invasive and does not require a biological sample from any individual.
The method differs fundamentally from personal drug testing. Saliva, urine and breath tests detect active substances or metabolites within a person’s body. Surface testing identifies environmental contamination that may have occurred recently, or in some cases weeks to months earlier, depending on the substance and the type of surface involved. The measurements are different too. Surface tests measure residue concentration in nanograms per square centimetre, while biological tests measure metabolites in blood, saliva or urine at different concentration units. These two types of measurement cannot be directly compared.
Surface testing is useful in several scenarios: assessing shared spaces before a new occupant moves in, identifying areas where drug use or handling has taken place, verifying the effectiveness of cleaning procedures and monitoring trends across a site over time. Because it examines property and objects rather than individuals, surface testing does not typically require personal consent from workers. However, it should always be conducted within a clear policy framework that the workforce has been informed about. Transparency about the purpose and scope of surface testing helps maintain trust and positions the program as a safety measure rather than covert surveillance.
Where Surface Testing Applies In Fifo And Remote Energy Operations
FIFO and remote energy sites create specific conditions that make surface testing particularly relevant. Workers live on site for extended periods in shared accommodation. Vehicles, workshops, mess halls and recreational areas are communal. The closed nature of these environments means that drug contamination in one area can point to broader risks across the facility. Personal testing at the gate catches workers who are currently impaired. Surface testing catches evidence of drug activity in the spaces where workers live and operate.
The most productive approach is targeted testing focused on high-touch areas where drug residue is most likely to accumulate. In FIFO accommodation, this includes room surfaces tested during turnovers between rosters or as part of periodic audits. In shared vehicles and light fleet, the priority areas are steering wheels, dashboards, gear shifters, cup holders and armrests. In workshops and operational areas, workbenches, tool handles and control panels are the primary targets. Break rooms, mess areas, bathrooms, amenity blocks and recreational spaces should also be included, particularly wet mess areas where off-duty drug use is more likely to occur.
Periodic testing creates a baseline for each area. Over time, trends become visible. If contamination levels in a particular building or vehicle pool decline after surface testing is introduced, the deterrence effect is working. If levels remain steady or spike in a specific location, that area may require additional investigation, changed access controls or more frequent cleaning protocols. This is intelligence-led safety management. It gives safety teams specific, actionable data rather than relying on assumptions about where risks are concentrated.
How It Works: The Drugsense Orascan System
The DrugSense OraScan Saliva and Surface Drug Test Cassette V5 is a dual-purpose testing cassette that detects six drug groups through either a saliva sample or a surface residue swab: amphetamines, methamphetamines, cocaine, opiates, oxycodone and THC. The cassette is verified to AS/NZS 4760:2019 for oral fluid testing. When used for surface testing, the same immunoassay technology is applied to detect drug residue collected from physical surfaces. Results are delivered in approximately three minutes.
For surface testing, a swab pad on the cassette is wiped across the target area to collect any residue present. The sample is then processed within the cassette using a reagent blister. The test window displays results for each of the six drug groups individually, giving the tester a clear indication of which substances have been detected. Each cassette carries a unique barcode, which prevents the use of expired materials and creates a traceable record from the moment the test begins.
When paired with the DrugSense OraScan 3000 Analyser, the system moves beyond visual interpretation into digital analysis. The analyser scans the cassette barcode, captures a photograph of the result window, records GPS coordinates, stores the result with associated subject or location details and prints a record on its built-in thermal printer. Results can be exported via USB, Wi-Fi or 4G. The device stores up to 100,000 records, making it suitable for sites that conduct high volumes of testing across both personal and surface applications.
For organisations managing multiple FIFO camps or remote facilities, the Andalink cloud platform provides the data management layer. Safety managers can view, download and manage results from multiple sites through a single system. Andalink allows teams to identify patterns across locations, track trends over time and generate reports that support both internal review and regulatory compliance. This centralised visibility is particularly valuable for operators who need to demonstrate consistent safety management across a portfolio of remote sites.
Surface Testing As Part Of A Layered Drug And Alcohol Program
Surface testing is not a replacement for personal screening. It is an additional control that strengthens the overall program by addressing a risk that oral fluid and breath alcohol testing cannot detect: environmental contamination and evidence of drug activity in shared spaces.
A layered testing program addresses different dimensions of impairment risk through complementary methods. Breath alcohol testing at site entry provides immediate detection of alcohol impairment before a worker begins a shift. Oral fluid drug screening detects recent drug use through a non-invasive saliva sample. Surface drug testing across accommodation, vehicles and communal areas detects evidence of drug activity in the physical environment. Urine testing, with its longer detection window, is suited to pre-employment checks or situations requiring broader historical screening. Each layer covers a different gap. Together, they create a program with significantly fewer blind spots than any single method used in isolation.
The OraScan Cassette V5 is particularly well suited to a layered approach because the same cassette can be used for both saliva screening and surface testing. This means a site does not need to stock separate consumable products for personal and environmental testing. It simplifies procurement, reduces inventory complexity and allows safety officers to switch between testing modes using a single familiar product. Training requirements are also streamlined because the collection and analysis process is consistent across both applications.
The Australian Petroleum Production and Exploration Association (APPEA) publishes Drug and Alcohol Guidelines for the Australian Petroleum Industry that support the adoption of comprehensive, risk-based impairment management programs. Under the Model Work Health and Safety Act administered by Safe Work Australia, officers have a personal duty to exercise due diligence in managing workplace risks. A layered testing program that includes surface testing demonstrates that the organisation has taken reasonable steps to identify and control impairment risks across both people and environments.
The Business Case: Why Surface Testing Pays Off
Organisations that have adopted surface testing alongside personal screening have reported measurable reductions in non-negative test results over time. This is a deterrence outcome, not a surveillance outcome. When workers know that shared spaces are being monitored for drug contamination, the incentive to bring substances on site decreases. The result is a safer environment with fewer positive test events, fewer incidents triggered by impairment and lower costs associated with managing the consequences.
The cost dynamics favour the investment. Surface testing with the OraScan system represents a low per-test outlay relative to the potential costs of a single drug-related incident on a remote site. A medical evacuation from a remote mining or energy operation can cost tens of thousands of dollars before the incident investigation, workers compensation claim, regulatory scrutiny, lost production time and reputational damage are factored in. Surface testing operates as a preventive control that reduces the likelihood of these events occurring. Viewed through this lens, the investment is not an additional expense. It is operational risk mitigation with a measurable return.
Surface testing also strengthens the organisation’s legal and compliance position. Under the Model Work Health and Safety Act, a Person Conducting a Business or Undertaking must manage risks so far as is reasonably practicable. If drug contamination in shared FIFO spaces is a foreseeable hazard, then implementing surface testing demonstrates that reasonable steps have been taken to identify and address it. This matters if an incident occurs and the adequacy of the safety program is examined by a regulator, insurer or court. WA mining operators, for example, are required under Regulation 641 of the Work Health and Safety (Mines) Regulations 2022 to manage risks associated with alcohol and drugs at the mine. Adding surface testing to the program provides documented evidence that the operator is managing environmental contamination risks alongside personal impairment risks.
Beyond compliance, surface testing contributes to the broader goal of building a workplace culture where safety is a shared value rather than a set of rules imposed from above. When testing is visible, consistent and clearly connected to protecting workers and the spaces they live in, it reinforces the message that the organisation takes safety seriously at every level.
A Practical Addition To Any Remote Site Safety Program
Surface drug testing is a practical, low-friction addition to any FIFO or remote energy site safety program. It addresses a layer of risk that personal testing alone cannot cover. It provides safety teams with specific, actionable data about the environments in which workers live and operate. It delivers measurable returns through deterrence, reduced non-negative rates and a strengthened compliance position. And it does this without the privacy and consent complexities that personal testing involves.
Andatech works with FIFO and remote site operators across Australia to design and implement layered testing programs that include surface testing alongside oral fluid screening, breath alcohol testing and urine-based programs. Speak with an Andatech specialist about layered testing programmes.
